Metropolis Healthcare METROPOLIS
Western and southern India pathology chain known for specialised tests, expanding by acquiring regional labs
Mapped in 1 theme: Hospitals & Healthcare.
Where Metropolis Healthcare sits in the supply chain
Metropolis Healthcare appears in 1 supply-chain layer in one theme, Hospitals & Healthcare.
Hospitals & Healthcare › Pathology labs
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 1,228 | 1,148 | 1,208 | 1,331 | 1,646 |
| Net profit | 215 | 143 | 128 | 146 | 191 |
Latest-year revenue ₹1,646 Cr (FY26, company-wide).
Strengths
- Strong in specialised and B2B testing for doctors and hospitals
- Acquisitions (Core Diagnostics and regional labs) widen the test menu and reach
- Q1 FY27 revenue grew ~17%, led by patient volumes (company results)
Risks
- Acquisition integration and goodwill
- Price competition in routine tests
Common questions
What does Metropolis Healthcare do?
Western and southern India pathology chain known for specialised tests, expanding by acquiring regional labs.
Where does Metropolis Healthcare sit in the supply chain?
Metropolis Healthcare (NSE: METROPOLIS) is mapped in 1 supply-chain layer: Pathology labs (Hospitals & Healthcare).
Who are Metropolis Healthcare's peers?
In the Pathology labs layer of Hospitals & Healthcare: Dr Lal PathLabs, Thyrocare Technologies, Vijaya Diagnostic Centre, Fortis Healthcare and Neuberg Diagnostics (not NSE-listed).
What is Metropolis Healthcare's market cap and valuation?
As of 6 Nov 2026: market cap ₹11,797 Cr, P/E 51.1x, ROCE 17.8%, ROE 13.6%, dividend yield 0.35%.